Materias dentro de su búsqueda.
Mostrando 461 - 480 Resultados de 1,900 Para Buscar '"AstraZeneca"', tiempo de consulta: 1.53s Limitar resultados
  1. 461
    “…Timothy H. Burgess, MD, MPH, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1884. Evaluating SARS-CoV-2 Surveillance Strategies at the United States Naval Academy: A Comparison of Saliva and Dried Blood Spot Serosurveillance Against Molecular-Confirmed Case Detection
  2. 462
    por Rose, Sophie, Rogers, Marc
    Publicado 2019
    “…This includes the Ion Channels in Drug Discovery XIX Satellite Meeting held at the 63rd Annual Meeting of the Biophysical Society (2019) and the Cambridge Ion Channel Symposium, cohosted by AstraZeneca and Metrion Biosciences.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Ion Channels Prominent at Key U.S. and U.K. Conferences
  3. 463
    por Park, Ji Yeon, Yi, Seong Yoon
    Publicado 2021
    “…We present the computed tomography, ultrasonographic findings of a case of contralateral supraclavicular lymphadenopathy that occurred after AstraZeneca COVID-19 vaccination. Contralateral supraclavicular lymphadenopathy is very rare, but may be expected as an adverse reaction after COVID-19 vaccination. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Rare case of contralateral supraclavicular lymphadenopathy after COVID-19 vaccination: Computed tomography and ultrasonography findings
  4. 464
    “…This study is one of the first in vivo studies that try to show the impact of Sinopharm (S) and AstraZeneca (A) vaccines on breast cancer, the most common cancer among women worldwide. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Anti-cancer effect of COVID-19 vaccines in mice models
  5. 465
    “…Fatal events were observed with Pfizer-BioNTech vaccine in three cases, and AstraZeneca and CoronaVac vaccines in one case each. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    COVID-19 vaccines safety: Spontaneous notification data
  6. 466
    por Grandy, S, Chapman, R H, Fox, K M
    Publicado 2008
    “…DISCLOSURES: SHIELD, the SHIELD Study Group and the preparation of this manuscript were supported by funding from AstraZeneca LP. Dr Grandy is an employee of AstraZeneca LP and Drs Chapman and Fox are independent consultants who received research funds to conduct this analysis.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Quality of life and depression of people living with type 2 diabetes mellitus and those at low and high risk for type 2 diabetes: findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD)
  7. 467
    “…He has led projects for health professionals and the community supported by governmental, community agency and pharmaceutical industry partners (Wyeth, Eli Lilly, Servier, Pfizer, AstraZeneca) for the identification and management of depression and anxiety. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Predicting early transition from sub-syndromal presentations to major mental disorders
  8. 468
    “…S. Ambrose, AstraZeneca: Employee, Salary and Stocks.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    728. Regional Validation of Distinct RSV Seasonality Thresholds for Antigen and PCR Testing
  9. 469
    “…The efficacy of Pfizer and Moderna for preventing disease or severe disease results 95–87.5% and 94.5–100%, respectively. The efficacy of Astra-Zeneca and Janssen is about 70% and 65%, respectively; in the case of Janssen, it depends on the geographical area ranging from 72% to 57%. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety
  10. 470
    por Dashdorj, Naranjargal J., Wirz, Oliver F., Röltgen, Katharina, Haraguchi, Emily, Buzzanco, Anthony S., Sibai, Mamdouh, Wang, Hannah, Miller, Jacob A., Solis, Daniel, Sahoo, Malaya K., Arunachalam, Prabhu S., Lee, Alexandra S., Shah, Mihir M., Liu, James, Byambabaatar, Sumiya, Bat-Ulzii, Purevjargal, Enkhbat, Anir, Batbold, Enkhtuul, Zulkhuu, Delgersaikhan, Ochirsum, Byambasuren, Khurelsukh, Tungalag, Dalantai, Ganbold, Burged, Natsagdorj, Baatarsuren, Uurtsaikh, Ariungerel, Nomin, Oidovsambuu, Odgerel, Bungert, Andreas S., Genden, Zulkhuu, Yagaanbuyant, Dahgwahdorj, Mordorj, Altankhuu, Pulendran, Bali, Chinthrajah, Sharon, Nadeau, Kari C., Jardetzky, Theodore, Wilbur, James L., Wohlstadter, Jacob N., Sigal, George B., Pinsky, Benjamin A., Boyd, Scott D., Dashdorj, Naranbaatar D.
    Publicado 2021
    “…We collected plasma specimens in July 2021 from 196 Mongolian participants fully vaccinated with one of four COVID-19 vaccines: Pfizer/BioNTech, AstraZeneca, Sputnik V, and Sinopharm. Functional antibody testing with a panel of nine SARS-CoV-2 viral variant receptor binding domain (RBD) proteins revealed marked differences in vaccine responses, with low antibody levels and RBD-ACE2 blocking activity stimulated by the Sinopharm and Sputnik V vaccines in comparison to the AstraZeneca or Pfizer/BioNTech vaccines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia
  11. 471
    “…A 21-year-old female patient developed an acute bilateral acute macular neuroretinopathy three days after receiving the first dose of SARS-CoV2-vaccine Vaxzevria(®) (AstraZeneca(®), Cambridge, UK). Conclusion: This case series describes six cases of retinal vascular events shortly after receiving mRNA or adenoviral-vectored COVID-19 vaccines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Retinal Vascular Events after mRNA and Adenoviral-Vectored COVID-19 Vaccines—A Case Series
  12. 472
    “…The World Health Organization has approved the safety and efficacy of the AstraZeneca/Oxford, Johnson and Johnson/Janssen (JnJ), Moderna, Pfizer/BioNTech, Sinopharm, and Sinovac vaccines so far. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cardiovascular Complications of SARS-CoV-2 Vaccines: An Overview
  13. 473
    “…DISCLOSURES: Jaime Fergie, MD, AstraZeneca (Scientific Research Study Investigator)Explify (Speaker’s Bureau)Karius (Speaker’s Bureau)Pfizer, Merck, AstraZeneca, and Sanofi (Speaker’s Bureau)Pfizer, Merck, Sanofi, and Moderna (Consultant, Advisor or Review Panel member)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1021. Utility of Cell-Free DNA Sequencing in Diagnosing Murine typhus in Children
  14. 474
    “…We aimed to illustrate the persistence of humoral response after receiving second dose of the Pfizer or AstraZeneca vaccines in patients under maintenance hemodialysis (HD). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Effectiveness of COVID-19 Vaccines in Patients Under Maintenance Hemodialysis
  15. 475
    “…From the total, 5,058,908 choose Pfizer–BioNTech, 399,327 Moderna, 419,037 AstraZeneca, and 1,913,978 Johnson & Johnson. With a cumulative 2147 local and 17,542 general adverse reactions, the most numerous were reported in recipients of Pfizer–BioNTech (1581 vs. 8451), followed by AstraZeneca (138 vs. 6033), Moderna (332 vs. 1936), and Johnson & Johnson (96 vs. 1122). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Mathematical Modeling to Predict COVID-19 Infection and Vaccination Trends
  16. 476
    “…The most commonly used vaccines in patients were Sinopharm [7 cases (50%)] and AstraZeneca [6 cases (42.9%)]. ARDs were significantly more common in subjects who received the AstraZeneca vaccine than in those who received other vaccines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Autoimmune inflammatory rheumatic diseases post-COVID‐19 vaccination
  17. 477
    “…Fourteen patients received Oxford/AstraZeneca. Only 2 patients received the Sputnik V vaccine. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Hospitalization among vaccines for SARS-CoV-2 breakthrough infection after dose sparing strategies in Libya: A cohort study
  18. 478
    “…De novo ITP was more likely after AstraZeneca ChAdOx1 nCoV-19 (89%) than Pfizer BNT162b2 (11%). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immune thrombocytopenia and COVID-19 vaccination: Outcomes and comparisons to prepandemic patients
  19. 479
    “…Finally, the numbers of oocytes were as follows: Johnson & Johnson (9.2 ± 2.6), AstraZeneca (7.7 ± 1.2), Moderna (11.3 ± 1.8), Pfizer (12.6 ± 1.0), and the unvaccinated group (10.2 ± 1.5), P=0.057. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The type of SARS-CoV-2 vaccine does not affect ovarian function in assisted reproduction cycle
  20. 480
    “…RESULTS: The vast majority of participants received Oxford/AstraZeneca ChAdOx1 as their first two doses and Moderna mRNA-1273 as their third dose. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Adverse events following the first, second and third doses of a COVID-19 vaccine in hemodialysis patients
Herramientas de búsqueda: RSS